Drugs / Paditaxel
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01474642 Comparator | Sep 2008 → Sep 2013 | esophageal squamous cell carcinoma | Samsung Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Paditaxel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01474642 ↗ |
| Known as | genexol | “Paditaxel(genexol)” NCT01474642 ↗ |
| Route | Intravenous | “Paditaxel(genexol) 80mg/m2 iv q 3 weeks” NCT01474642 ↗ |